Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-01
2008-04-01
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S217050, C514S253040, C540S599000, C544S121000, C544S362000
Reexamination Certificate
active
07351708
ABSTRACT:
The present invention relates to compounds of formula Iwherein R1to R4are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
REFERENCES:
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 4931463 (1990-06-01), Barbier et al.
patent: 4983746 (1991-01-01), Barbier et al.
patent: 5175186 (1992-12-01), Barbier et al.
patent: 5246960 (1993-09-01), Barbier et al.
patent: 5399720 (1995-03-01), Karpf et al.
patent: 6004996 (1999-12-01), Shah et al.
patent: 2004/0176598 (2004-09-01), Dugar
patent: 0 189 577 (1989-12-01), None
patent: 0 185 359 (1991-12-01), None
patent: 0 524 495 (1996-10-01), None
patent: 0 443 449 (1997-05-01), None
patent: WO 99/34786 (1999-07-01), None
patent: WO 00/09122 (2000-02-01), None
patent: WO 00/09123 (2000-02-01), None
patent: WO 00/44753 (2000-08-01), None
patent: WO 03/064423 (2003-08-01), None
patent: WO 2004/035556 (2004-04-01), None
patent: WO 2004/104001 (2004-12-01), None
patent: WO 2005/097740 (2005-10-01), None
Phillips et al. Annual Reports in medicinal Chemistry, vol. 33,p. 31-40 (1998).
Passani et al. Neuroscience and Biobehavioral Reviews, vol. 24, p. 107-113 (2000).
Leurs et al. TIPS, vol. 19, p. 177-183 (1998).
Burks 1994 in Johnson L.R. ed., Physiology of the Gastrointestinal Tract, Raven Press, NY, pp. 211-242.
Leurs et al., Br J. Pharmacol. 1991, 102, pp. 179-185.
Raithel et al., Int. Arch. Allergy Immunol. 1995, 108, 127-133.
Panula et al., Proc. Natl. Acad. Sci. USA 1984, 81, 2572-2576.
Inagaki et al., J. Comp. Neurol 1988, 273, 283-300.
Arrang et al., Nature 1983, 302, 832-837.
Arrang et al., Neuroscience 1987, 23, 149-157.
Clapham & Kilpatrik, Br. J. Pharmacol. 1982, 107, 919-923.
Leurs RL and Timmermann H eds, 1998, pp. 27-40, Elsevier, Amsterdam, The Netherlands.
Masaki et al; Endocrinol. 2003, 144, 2741-2748.
Hancock et al., European J. of Pharmacol. 2004, 487, 183-197.
Timmermann, J. Med. Chem. 1990, 33, 4-11.
W.W.K.R. Mederski et. al, Tetrahedron, 1999, 55, 12757.
Takahashi, K, Tokita, S., Kotani, H. (2003) J. Pharmacol. Exp. Therapeutics 307, 213-218.
Cheng, Y, Prusoff, WH (1973) Biochem Pharmacol 22, 3099-3108.
Stark H., Exp Opin on Thera, V.13, N.6 (2003) 851-865.
Nettekoven Matthias
Roche Olivier
Bernhardt Emily
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Tramaloni Dennis P.
LandOfFree
Pyrrolo [2,3-b] pyridine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolo [2,3-b] pyridine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo [2,3-b] pyridine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2746749